| 產(chǎn)品編號 | bs-0530R |
| 英文名稱 | Rabbit Anti-PPAR gamma antibody |
| 中文名稱 | 過氧化酶活化增生受體γ抗體 |
| 別 名 | GLM1; CIMT1; NR1C3; PPARG; PPARG1; PPARG2; PPARG5; PPARgamma; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; PPARG_HUMAN; PPAR-γ; PPAR γ; PPARγ; |
 |
Specific References (44) | bs-0530R has been referenced in 44 publications.
|
| 研究領(lǐng)域 | 免疫學 信號轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 糖尿病 內(nèi)分泌病 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Sheep,Cow,Chicken) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1μg/Test,ICC/IF=1:100,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 57kDa |
| 細胞定位 | 細胞核 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PPAR Gamma: 101-200/505 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008] Function: Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Subunit: Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with TGFB1I1. Interacts with DNTTIP2. Interacts with PRMT2. Subcellular Location: Nucleus. Tissue Specificity: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary. DISEASE: Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia. Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility. Similarity: Belongs to the nuclear hormone receptor family. NR1 subfamily. Contains 1 nuclear receptor DNA-binding domain. SWISS: P37231 Gene ID: 5468 Database links: Entrez Gene: 5468 Human Entrez Gene: 19016 Mouse SwissProt: P37231 Human SwissProt: P37238 Mouse Unigene: 162646 Human Unigene: 3020 Mouse Unigene: 23443 Rat 類固醇受體（Steroid Receptors） 過氧化物酶體增殖物激活受體γ（PPARγ）主要存在于白色脂肪組織，PPARγ對于脂肪生成、血糖穩(wěn)定、炎癥反應(yīng)、動脈粥樣硬化和腫瘤等的發(fā)生都起到重要的作用。主要在脂肪細胞內(nèi)表達。PPARγ是噻唑烷二酮類藥物（TZDs）作用的藥靶，又是脂肪細胞分化的重要調(diào)節(jié)因子。經(jīng)研究發(fā)現(xiàn)，PPARγ在肥胖及胰島素抵抗的發(fā)病機制中具有十分重要的意義，是治療糖尿病、肥胖等代謝性疾病的重要藥靶。 過氧化物酶體增殖物激活受體γ（PPARγ）屬Ⅱ型核受體超家族成員，主要在脂肪細胞內(nèi)表達。PPARγ是噻唑烷二酮類藥物（TZDs）作用的藥靶，又是脂肪細胞分化的重要調(diào)節(jié)因子?，F(xiàn)有研究（包括一次于美國加州大學進行的研究）發(fā)現(xiàn)PPARγ在肥胖及胰島素抵抗的發(fā)病機制中具有十分重要的意義，是治療糖尿病、肥胖等代謝性疾病的重要藥靶。目前，該受體蛋白質(zhì)水平的篩選模式已經(jīng)建立，并正在建立該受體的報告基因的細胞水平篩選評價模式。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Breast tissue lysates
Lane 2: Mouse Lung tissue lysates
Lane 3: Rat Adipose tissue lysates
Lane 4: Rat Breast tissue lysates
Lane 5: Rat Lung tissue lysates
Lane 6: Human A431 cell lysates
Lane 7: Human A549 cell lysates
Lane 8: Human THP-1 cell lysates
Lane 9: Human 293T cell lysates
Primary: Anti-PPAR gamma (bs-0530R) at 1/500 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57 kDa
Observed band size: 52 kDa
Paraformaldehyde-fixed, paraffin embedded (mouse placenta); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PPAR gamma) Polyclonal Antibody, Unconjugated (bs-0530R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Tissue/cell: mouse lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-PPAR Gamma Polyclonal Antibody, Unconjugated(bs-0530R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: A549 cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (PPAR gamma) polyclonal Antibody, Unconjugated (bs-0530R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Blank control (blue line): U251
Primary Antibody (green line): Rabbit Anti-PPARG/PPAR gamma antibody (bs-0530R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody (white blue line): Goat anti-rabbit IgG-FITC
Dilution: 1μg /test.
Protocol
The cells were fixed with 70% ethanol (Overnight at 4℃) and then permeabilized with 90% ice-cold methanol for 30 min on ice. Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control: A431.
Primary Antibody (green line): Rabbit Anti-PPAR gamma antibody (bs-0530R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody : Goat anti-rabbit IgG-AF647
Dilution: 1μg /test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at-20℃. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
